Apnimed to seek approval for sleep apnoea pill after Phase III success
Apnimed’s oral sleep apnoea therapy AD109 has met the primary endpoint in a Phase III trial, with hopes to file…
Respiratory
-
-
Rejuvenate Biomed doses first subject in COPD-related muscle weakness trial
Rejuvenate Biomed has dosed the first subject in the randomised Phase II trial to assess its lead compound, RJx-01, for…
-
Nuance seeks China approval for Ohtuvayre following Phase III trial success
Nuance Pharma’s Ohtuvayre (ensifentrine) has met the primary endpoint in a Phase III chronic obstructive pulmonary disease (COPD) study in…
-
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial
Revolution Medicines has dosed the first subject in the Phase III RASolve 301 trial with the RAS (ON) multi-selective inhibitor,…
-
Connect Biopharma begins Phase II trial of drug for acute exacerbations in asthma
US-based biopharmaceutical company Connect Biopharma has started a Phase II trial to assess the efficacy and safety of rademikibart in…
-
OmRx Oncology begins Phase II trial of oral PD-L1 inhibitor for NSCLC
Clinical-stage biopharmaceutical venture OmRx Oncology (OmRx) has commenced a randomised Phase II clinical trial for its oral programmed death ligand…
-
Pliant cuts workforce by 45% following lung trial termination
Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the…
-
AstraZeneca’s triple-combo triumphs in two Phase III asthma trials
AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) has met the primary endpoints in two Phase III asthma trials. Breztri met…
-
Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment
Rein Therapeutics has announced a partnership to integrate UK-based core imaging laboratory Qureight’s deep-learning platform into the upcoming Phase II trial…
-
Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC
Amgen's global Phase III DeLLphi-304 trial of Imdelltra (tarlatamab-dlle) has met its primary endpoint at a planned interim analysis for…
